Studies Open for Enrollment

The use of Formula Fortified with Docosahexaenoic acid in Infants with Cystic Fibrosis

The goal of this research is to see if what infants are fed in the first year of life affects the course of their Cystic Fibrosis (CF) disease. There is some evidence that certain fats in the diet may play an important role for children with CF. This study may determine if giving formula fortified with Docosahexaenoic acid (DHA) can provide protection from lung and pancreas disease. Participants will be randomly assigned to receive either traditional formula (Enfamil®) or the DHA-containing formula (LIPIL® x 3). Approximately 20 infants, both male and female, will take part in this study at Children’s Hospital of Pittsburgh of UPMC as part of this multi-site study.

Candidates
Newborns diagnosed with CF, ages birth through 56 days, who are bottle-fed.
Boys: Birth to 8 weeks
Girls: Birth to 8 weeks

Requirements
Routine questions and examination will occur at each clinic visit, along with a throat culture, blood draw, and stool collection.
Visits: 5
Duration: 12 months

Status: Open for Enrollment

How to Participate
To get started, please contact either:
Elizabeth Hartigan, RN
Sandy Hurban, RN
Adrienne Horn, RN
1-877-296-9026

Additional Resources
Cystic Fibrosis

Principal Investigator
Daniel Weiner, MD
Pulmonology Laboratory

Source of Support
Mead-Johnson
Cystic Fibrosis Foundation